This article provides a head-to-head comparison of IQVIA and FOXO Technologies, two medical companies. It examines factors such as institutional ownership, risk, earnings, valuation, profitability, analyst recommendations, and dividends. IQVIA is considered more favorable by analysts due to its higher potential upside and higher institutional ownership, indicating long-term growth potential. In terms of volatility, IQVIA has a beta of 1.39, while FOXO Technologies has a beta of 2.05, making it more volatile. The article gives a brief overview of IQVIA's business, which includes advanced analytics, technology solutions, and clinical research services for the life sciences industry. FOXO Technologies, on the other hand, focuses on epigenetic biomarker underwriting technology and consumer engagement platform services. The article also mentions earnings forecasts for other companies, such as Amkor Technology and SoFi Technologies.
Source: Defense World [adcddb41]
Image: 